==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb

This page displays user query in tabular form.

1637 details
Primary information
ThPP IDTh1143
Therapeutic Peptide/Protein NameFibrinolysin aka plasmin
SequenceFibrinolysin heavy chainDLLDDYVNTQGASLLSLSRKNLAGRS view full sequnce in fasta
Functional ClassificationIc
Molecular Weight88400
Chemical FormulaC3848H5912N1096O1185S60
Isoelectric PointN.A.
HydrophobicityN.A.
Melting Point (℃)N.A.
Half Life24 hrs
DescriptionDerived from bovine plasma or extracted from bacterial cultures. It is a globular protein with a molecular weight of ~90 kDa. Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. The light chain has a molecular weight of approximately 27 kDa and contains the active center of fibrinolysin; the heavy chain has a molecular weight of approximately 57 kDa. It is used as a local healing ointment when combined with the enzyme deoxyribonuclease I (derived from bovine pancreas). Fibrinolysin and deoxyribonuclease both act as lytic enzymes. The combination is available as ointment containing 1 BU (Biological Unit) fibrinolysin and 666 BUs deoxyribonuclease per gram. The ointment (Fibrolan) is marketed by Pfizer in a variety of countries is currently not approved in the USA.
Indication/DiseaseFibrinolysin assists with the healing of minor burns, superficial wounds, ulcers, surgical wounds, and superficial hematomas.
PharmacodynamicsN.A.
Mechanism of ActionFibrinolysin attacks and inactivates fibrin molecules occurring in undesirable exudates on the surface of the human body and on human mucosa, e.g., in superficial wounds and burns, while desoxyribonuclease targets and destroys (human) DNA. The combination of the two enzymes has a synergistic effect on necrotic but not on living tissue.
ToxicityN.A.
Metabolismlocal inactivation.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesN.A.
Patents NumberUS3234106
Date of Issue13/03/66
Date of Expiry13/03/86
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameElase
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearnceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://en.wikipedia.org/wiki/Fibrinolysin http://www.drugs.com/international/fibrinolysin.html
PubMed ID6226244
3-D StructureTh1143 Heavy chianor (Download)Th1143 Light chian (View) or (Download) Th1191 Heavy chianor (Download)Th1191 Light chian (View) or (Download)